Cargando…
ASA404, a vascular disrupting agent, as an experimental treatment approach for brain tumors
Malignant brain tumors, including gliomas, brain metastases and anaplastic meningiomas, are associated with poor prognosis, and represent an unmet medical need. ASA404 (DMXAA), a vascular disrupting agent, has demonstrated promising results in several preclinical tumor models and early phase clinica...
Autores principales: | Bähr, Oliver, Gross, Stefanie, Harter, Patrick N., Kirches, Elmar, Mawrin, Christian, Steinbach, Joachim P., Mittelbronn, Michel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652230/ https://www.ncbi.nlm.nih.gov/pubmed/29098034 http://dx.doi.org/10.3892/ol.2017.6832 |
Ejemplares similares
-
The influence of the combined treatment with Vadimezan (ASA404) and taxol on the growth of U251 glioblastoma xenografts
por: Milanović, Dušan, et al.
Publicado: (2012) -
Fermented Mistletoe Extract as a Multimodal Antitumoral Agent in Gliomas
por: Podlech, Oliver, et al.
Publicado: (2012) -
Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer
por: McKeage, M J, et al.
Publicado: (2008) -
Bevacizumab for Patients with Recurrent Gliomas Presenting with a Gliomatosis Cerebri Growth Pattern
por: Burger, Michael C., et al.
Publicado: (2017) -
Hypoxia Enhances the Antiglioma Cytotoxicity of B10, a Glycosylated Derivative of Betulinic Acid
por: Fischer, Sebastian, et al.
Publicado: (2014)